Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-08-09
DOI
10.3389/fimmu.2021.705096
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of Immune-Related Prognostic Biomarkers Associated with HPV-Positive Head and Neck Squamous Cell Carcinoma
- (2021) Yifei Chen et al. Journal of Immunology Research
- Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma
- (2021) Peng Zhu et al. MEDICINE
- Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
- (2020) Andrea Botticelli et al. Journal of Translational Medicine
- Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
- (2020) Jiahang Mo et al. World Journal of Surgical Oncology
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis
- (2020) Ashley Lau et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
- (2020) Alessio Cortellini et al. EUROPEAN JOURNAL OF CANCER
- The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
- (2020) Andrea Botticelli et al. Vaccines
- The 5-Ws of immunotherapy in head and neck cancer
- (2020) Andrea Botticelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
- (2020) Paolo Marchetti et al. Journal of Translational Medicine
- The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors
- (2019) Kyung Hwan Kim et al. CLINICAL CANCER RESEARCH
- A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
- (2019) Andrea Botticelli et al. Journal of Translational Medicine
- Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
- (2019) Elie El Rassy et al. Future Oncology
- Sex hormones and anticancer immunity
- (2019) Berna C. Özdemir et al. CLINICAL CANCER RESEARCH
- CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
- (2019) Benedetto Sacchetti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Joel Guigay et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor‐infiltrating lymphocyte quantification stratifies early‐stage human papillomavirus oropharynx cancer prognosis
- (2019) Farhoud Faraji et al. LARYNGOSCOPE
- Advances in the Management of HPV-Related Oropharyngeal Cancer
- (2019) F. De Felice et al. Journal of Oncology
- The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
- (2019) Hao Chen et al. CANCER SCIENCE
- Macrophages and Metabolism in the Tumor Microenvironment
- (2019) Ilio Vitale et al. Cell Metabolism
- Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
- (2019) Mark Lee et al. Human Vaccines & Immunotherapeutics
- Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
- (2019) Mehmet Asim Bilen et al. BMC CANCER
- Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma
- (2019) Talia L. Fuchs et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Melanoma: prognostic factors and factors predictive of response to therapy
- (2019) Martina Strudel et al. CURRENT MEDICINAL CHEMISTRY
- CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer
- (2019) Bruna Cerbelli et al. VIRCHOWS ARCHIV
- First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
- (2018) Christopher J.D. Wallis et al. EUROPEAN UROLOGY
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Immunotherapy in head and neck cancer – scientific rationale, current treatment options and future directions
- (2018) SWISS MEDICAL WEEKLY
- The Confluence of Sex Hormones and Aging on Immunity
- (2018) Melanie R. Gubbels Bupp et al. Frontiers in Immunology
- A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
- (2018) S. N. Gettinger et al. Nature Communications
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
- (2018) Dan P. Zandberg et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
- (2018) Yi Ming Weng et al. OncoTargets and Therapy
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
- (2017) P. S. Chowdhury et al. JOURNAL OF INTERNAL MEDICINE
- Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
- (2017) Kentaro Inamura et al. LUNG CANCER
- The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
- (2017) Andrea Botticelli et al. Oncotarget
- Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma
- (2017) Yubo Jiang et al. Oncotarget
- PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
- (2017) Bruna Cerbelli et al. Biomed Research International
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational signatures associated with tobacco smoking in human cancer
- (2016) L. B. Alexandrov et al. SCIENCE
- Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
- (2015) J. Guigay et al. ANNALS OF ONCOLOGY
- Ranking treatments in frequentist network meta-analysis works without resampling methods
- (2015) Gerta Rücker et al. BMC Medical Research Methodology
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- (2015) Assuntina G. Sacco et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
- (2014) Joseph M. Curry et al. SEMINARS IN ONCOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Network meta-analysis, electrical networks and graph theory
- (2012) Gerta Rücker Research Synthesis Methods
- HPV and head and neck cancer
- (2011) X. Dufour et al. European Annals of Otorhinolaryngology-Head and Neck Diseases
- T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer
- (2010) A. E. Albers et al. Clinical & Developmental Immunology
- Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
- (2009) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Recent Advances in Head and Neck Cancer
- (2008) Robert I. Haddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now